

CITATION REPORT

List of articles citing

Mosunetuzumab: First Approval

DOI: 10.1007/s40265-022-01749-5
, 2022, 82, 1229-1234.

Source: <https://exaly.com/paper-pdf/149979105/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Immunotherapeutic progress and application of bispecific antibody in cancer. 13,		1
5	End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations. 2023 , 5, 100157		0
4	Alternative splicing of its 5' untranslated region controls CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.		0
3	Strategies for clinical dose optimization of T cell-engaging therapies in oncology. 2023 , 15,		0
2	Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab. Volume 15, 257-264		0
1	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.		0